Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
The invention provides a new use of landiolol hydrochloride for persistent reduction of the heart rate during the administration period of landiolol hydrochloride in the treatment of a human suffering from tachycardia, tachyarrhythmia or elevated blood pressure, wherein landiolol hydrochloride is administered at a constant dose of more than 5 μg/kg/min, specifically of at least 10 μg/kg/min for a period of at least 2 hours and wherein the heart rate and/or blood pressure of said patient are persistently reduced during the administration period compared to the heart rate and/or blood pressure before treatment and no overshooting effect occurs after termination of said administration.
1. A method of reducing the heart rate of a subject suffering from supraventricular tachycardia, wherein the method consists of the step of administering landiolol hydrochloride parenterally to the subject at a constant dose of more than 20 μg/kg/min for a period of from 2 to 20 hours, wherein the dose is not higher than 40 μg/kg/min.
2. The method of claim 1 , wherein the constant dose of landiolol hydrochloride is at least 25 μg/kg/min, at least 30 μg/kg/min, or at least 35 μg/kg/min.
3. The method of claim 1 , wherein landiolol hydrochloride is administered for at least 4 hours, for at least 6 hours, or for at least 12 hours.
4. The method of claim 1 , wherein the heart rate of the subject is reduced by at least 5%, or by between 10% and 50%, compared to the heart rate of the subject before the administration of landiolol hydrochloride.
5. The method of claim 1 , wherein no overshoot effect occurs after termination of the administration of landiolol hydrochloride to the subject.
6. The method of claim 1 , wherein the subject's heart reaches a normal rate within 5 to 20 minutes after termination of administration of landiolol hydrochloride to the subject.
7. The method of claim 1 , wherein said landiolol hydrochloride is at a concentration of about 1 mg/mL to 30 mg/mL, or at a concentration of about 5 to 15 mg/mL.
8. The method of claim 1 , wherein said landiolol hydrochloride is provided as a solution.
9. The method of claim 8 , wherein said solution has a pH of up to 6.5.
10. The method of claim 8 , wherein said solution is administered by a route selected from the group consisting of subcutaneous administration, intravenous administration, intraarterial administration, and intracoronary administration.
11. The method of claim 8 , wherein said solution is local tissue tolerant at the infusion site, thereby preventing local venous irritation or skin necrosis at the infusion site.
12. The method of claim 1 , wherein said subject is suffering from intoxication due to a positive intotropic drug or a sympathomimetic drug.
13. The method of claim 8 , wherein the solution is prepared by reconstituting a lyophilized powder comprising landiolol hydrochloride.
14. The method of claim 10 , wherein the solution of landiolol hydrochloride is administered as a continuous intravenous infusion.
15. The method of claim 1 , wherein said landiolol hydrochloride is provided for a period of up to 4 hours.